Faslodex Alternatives Compared
| Faslodex | Ibrance | Letrozole |
|
|---|
| Faslodex (fulvestrant) | Ibrance (palbociclib) | Letrozole |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Faslodex may be used alone or in combination with other agents for the treatments of certain types of breast cancer in postmenopausal women or women with disease progression following endocrine... View more |
Prescription only
Ibrance is a CDK4/6 inhibitor that may be used to treat advanced or metastatic hormone-receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer in combination... View more |
Prescription only
Letrozole is a treatment that may be used to reduce the risk of breast cancer recurrence in postmenopausal women and also to increase the chance of ovulation in women with polycystic ovary syndrome... View more |
Related suggestions Breast Cancer
Breast Cancer, Metastatic
|
|||||||||||||||||||||||
| More about Faslodex (fulvestrant) | More about Ibrance (palbociclib) | More about Letrozole | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
|
No lower-cost generic available |
No lower-cost generic available |
|||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Faslodex has an average rating of 6.1 out of 10 from a total of 28 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 29% reported a negative effect. |
Ibrance has an average rating of 6.6 out of 10 from a total of 70 ratings on Drugs.com. 61% of reviewers reported a positive effect, while 32% reported a negative effect. |
Letrozole has an average rating of 6.4 out of 10 from a total of 337 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 24% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
See also: Faslodex side effects in more detail. |
Common side effects include:
See also: Ibrance side effects in more detail. |
Commonly reported side effects include:
See also: letrozole side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Faslodex prices |
View all Ibrance prices |
View all letrozole prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
Femara | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
960 hours |
29 hours |
48 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 2 drugs are known to interact with Faslodex:
|
A total of 421 drugs are known to interact with Ibrance:
|
A total of 103 drugs are known to interact with letrozole:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
February 03, 2015 |
June 03, 2011 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.